| Metric | FY 2026 | FY 2025 |
|---|---|---|
| Revenue | 0.1 | — |
| Net income | -3.6 | -178.0 |
| EPS (diluted, $ a share) | $-1.06 | $-86.27 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-K filed with the SEC, NASDAQ: LNAI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lunai Bioworks Inc.: key numbers
- Share price
- $0.1648Close, Oct 29
- Market cap
- $830K
- Shares outstanding
- 5.03MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lunai Bioworks Inc.
All →Lunai Bioworks Executive Compensation
Lunai Bioworks entered into an amended employment agreement with CEO David Weinstein, reducing his annual base salary from $400,000 to $275,000. Weinstein waived his rights to severance and accelerated vesting, and his employment term was set to end on December 28, 2026. The agreement also terminates his non-competition and non-solicitation covenants while deferring his October 2026 salary payment.
- Counterparty
- David Weinstein
- Term
- through Dec 2026
Lunai Bioworks Nasdaq/NYSE Compliance Notice
Lunai Bioworks received a Nasdaq delisting determination for failing to maintain the minimum stockholders' equity requirement of $2.5 million, reporting a deficit of over $9 million. The company has decided not to appeal the decision and will voluntarily delist its common stock from Nasdaq and deregister with the SEC to save costs.
- Counterparty
- Nasdaq
Lunai Bioworks Court & Legal Update
Lunai Bioworks has requested that Nasdaq immediately suspend trading of its common stock (LNAI) due to evidence of irregular trading activity uncovered during discovery in its pending litigation against Seven Points Capital LLC. The company alleges substantial short selling, locate deficiencies, and concentrated failures to deliver that may indicate the market for its shares is not fair or orderly. Nasdaq has not yet made a decision on the request, and the underlying litigation in the U.S. District Court for the District of Delaware remains ongoing.
- Counterparty
- Seven Points Capital LLC